You are here

Non-invasive Prenatal Testing (NIPT) Market - Worldwide Review & Forecast (2019-2025): Revenue Projected at $4.97 Billion by 2025

DUBLIN, March 28, 2019 /PRNewswire/ -- The "Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to's offering.

Global Non-Invasive Prenatal Testing Market Expected to Witness a CAGR of 17.5% to Reach Revenues of $4.97 Billion by 2025

The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market.

The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.

The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology.

Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.

According to analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide.

The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24-25 years with incidence rate reduced to 1 in 1429.

The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region.

Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.

By Application:

  • Trisomy
  • Microdeletion Syndrome
  • Other NIPT Applications

In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.

By Regions:

  • North America
  • Europe
  • APAC
  • RoW

The global market is dominated by North America, followed by Europe and Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.

Competitive Analysis

The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity.

10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018.

In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Agncia Nacional de Vigilncia Sanitria, for sale in the country as an IVD.

In late 2018, PerkinElmer's Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017.

In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of the Europe's specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.

Key Vendors:

  • Natera Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Illumina Inc.
  • F. Hoffmann-La Roche
  • Beijing Genomics Institute
  • LifeCodexx AG
  • Quest Diagnostics
  • Yourgene Health PLC
  • Myriad Genetics Inc.
  • NIPD Genetics
  • PerkinElmer Inc.
  • Next Biosciences (Pty) Limited

Key Competitive Facts

The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.

The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.

Key Takeaways

  • Understanding the potential market opportunity with precise market size and forecast data.
  • A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
  • Factors influencing the growth of the non-invasive prenatal testing market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
  • Key insights related to major segments of the non-invasive prenatal testing market.
  • Latest market trend analysis impacting the buying behavior of the consumers.

Topics Covered

1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition
3.2 Device Benefits
3.3 Segmented Addressable Market
3.4 Trends in the Non-invasive Prenatal Testing Market
3.5 Related Markets
3.5.1 Genetic Testing
3.5.2 Cell-free DNA Testing
3.5.3 Transplantation Diagnostics
3.5.4 Liquid Biopsy

4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 Forces

5 Market Characteristics
5.1 DRO - Market Dynamics
5.1.1 Drivers Upsurge in the Number of Babies with Chromosomal Disorders due to Increasing Number of Late Pregnancies Growing Demand for Non-Invasive Procedures for Early Diagnosis
5.1.2 Opportunities Increase in Healthcare Spending and Growing Healthcare Awareness in Emerging Economies Rising Number of Deals Related to the Technology
5.1.3 Restraints High Cost of the Test with Less Reimbursement Facilities Ethical Concerns Related to the Technology
5.2 DRO - Impact Analysis
5.3 Key Stakeholders

6 Applications: Market Size and Analysis
6.1 Overview
6.2 Trisomy
6.3 Microdeletion Syndrome
6.4 Other NIPT Applications

7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.3 Europe
7.4 Asia Pacific
7.5 Rest of the World

8 Competitive Landscape

9 Vendor Profiles
9.1 Natera Inc.
9.1.1 Overview
9.1.2 Geographic Presence
9.1.3 Business Focus
9.1.4 SWOT Analysis
9.1.5 Business Strategies
9.2 Illumina Inc.
9.3 Laboratory Corporation of America Holdings (LabCorp)
9.4 F. Hoffmann-La Roche Ltd.
9.5 Beijing Genomics Institute

10 Companies to Watch For
10.1 Quest Diagnostics
10.2 LifeCodexx AG
10.3 Yourgene Health PLC
10.4 NIPD Genetics
10.5 Myriad Genetics Inc.
10.6 PerkinElmer Inc.
10.7 Next Biosciences (Pty) Limited

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets